Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 215
Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C B Public Meeting Agendas FIRST MEETING-DECEMBER 4, 2008 National Academy of Sciences Building, Washington, DC Welcome and opening statement Palmer Beasley, Committee Chair Charge to the committee John Ward, Centers for Disease Control and Prevention (CDC) Chris Taylor and Martha Saly, National Viral Hepatitis Roundtable Presentations to the committee Dale Hu, CDC Broad Overview of Hepatitis B Cindy Weinbaum, CDC Broad Overview of Hepatitis C Lorren Sandt, Caring Ambassadors Program Hepatitis C: Moving Beyond the Silence
OCR for page 216
Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C Joan Block, Hepatitis B Foundation Hepatitis B: Time for Zero Tolerance Public comment period SECOND MEETING-MARCH 3, 2009 The National Academies Beckman Center, Irvine, California Welcome and opening statement Palmer Beasley, Committee Chair Presentations to the committee Gary Heseltine Lead Consultant, Viral Hepatitis Team, Council of State and Territorial Epidemiologists Surveillance Strengths and Weaknesses William Rogers Director of CMS, Physician’s Regulatory Issues Team Viral Hepatitis Prevention Policies and Programs, Centers for Medicare and Medicaid (CMS) Tanya Pagán Raggio Ashley Director, Office of Minority Health and Health Disparities, and Chief Medical Officer, HRSA Community Health Centers: Health Resources and Services Administration (HRSA) Policies and Programs Daniel Raymond Policy Director, Harm Reduction Coalition Hepatitis C Prevention: Harm Reduction David Bell Associate Director for Science and Global Activities, Division of Viral Hepatitis, Centers for Disease Control and Prevention Global Viral Hepatitis Burden: Implications for the US and CDC Response
OCR for page 217
Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C Mark Kane Former Director of the Children’s Vaccine Program, PATH Global Control Programs and HBV Immunization Question and answer period
OCR for page 218
Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C This page intentionally left blank.